Interprofessional evidence-based counselling programme for complementary and integrative healthcare in patients with cancer: study protocol for the controlled implementation study CCC-Integrativ.
adult oncology
complementary medicine
herbal medicine
nutritional support
oncology
preventive medicine
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
11 Feb 2022
11 Feb 2022
Historique:
entrez:
12
2
2022
pubmed:
13
2
2022
medline:
21
4
2022
Statut:
epublish
Résumé
According to international literature, patients with cancer wish to have information on complementary and integrative healthcare (CIH). Medical guidelines recommend actively approaching patients with cancer discussing potential benefits and risks of individual CIH methods. While some CIH methods, for example, acupuncture and yoga, have been proven effective in high-quality studies, other CIH methods lack studies or bear the risk of interactions with chemotherapeutics, for example, herbal drugs. Therefore, an evidence-based interprofessional counselling programme on CIH will be implemented at four Comprehensive Cancer Centres in the federal state of Baden-Wuerttemberg, Germany. A complex intervention consisting of elements on patient, provider and system levels will be developed and evaluated within a multilayer evaluation design with confirmatory evaluation on patient level. Patients with a cancer diagnosis within the last 6 months will receive three individual counselling sessions on CIH within 3 months (=intervention on patient level). The counselling will be provided by an interprofessional team of medical and nursing staff. For this purpose, an intensive online training programme, a CIH knowledge database and an interprofessional team-building process were developed and implemented (=intervention on provider level). Moreover, training events on the basics of CIH are offered in the outpatient setting (=intervention on system level). Primary outcome of the evaluation at the patient level is patient activation measured (PAM) with the PAM-13 after 3 months. Secondary outcomes, for example, quality of life, self-efficacy and clinical parameters, will be assessed at baseline, after 3 months and at 6 months follow-up. The intervention group (n=1000) will be compared with a control group (n=500, treatment as usual, no CIH counselling. The outcomes and follow-up times in the control group are the same as in the intervention group. Moreover, the use of health services will be analysed in both groups using routine data. A qualitative-quantitative process evaluation as well as a health economic evaluation will identify relevant barriers and enabling factors for later roll-out. The study has been approved by the appropriate Institutional Ethical Committee of the University of Tuebingen, No. 658/2019BO1. The results of these studies will be disseminated to academic audiences and in the community. DRKS00021779; Pre-results.
Identifiants
pubmed: 35149568
pii: bmjopen-2021-055076
doi: 10.1136/bmjopen-2021-055076
pmc: PMC8845169
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e055076Investigateurs
A Schmitt
(A)
B Kröger
(B)
B Noack
(B)
B Wattenberg
(B)
E Kaschdailewitsch
(E)
H Mauch
(H)
K Gauß
(K)
K Harder
(K)
L Lohmüller
(L)
A Seckinger
(A)
D Zips
(D)
K Müller
(K)
E Winkler
(E)
M Busacker-Scharpff
(M)
M Hoffmann
(M)
M Krug
(M)
M Reuter
(M)
S Eismann
(S)
A Kestler
(A)
B Leicht
(B)
C Nagat
(C)
C Raff
(C)
F Rapp
(F)
K Kraus
(K)
W Kmietschak
(W)
A Battran
(A)
A Frohn
(A)
B Held
(B)
C Perinchery
(C)
C Pfister-Jimenéz
(C)
H Dürsch
(H)
J Bossert
(J)
J Szecsenyi
(J)
M Wensing
(M)
A Kaltenbach
(A)
U Boltenhagen
(U)
A Behzad
(A)
A Leppert
(A)
B Stein
(B)
B Broge
(B)
C Witte
(C)
S Treffert
(S)
Aok Baden-Württemberg
(A)
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
JAMA Oncol. 2018 Oct 1;4(10):1375-1381
pubmed: 30027204
Clin Med (Lond). 2013 Feb;13(1):7-12
pubmed: 23472485
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
PLoS One. 2013 Sep 30;8(9):e74786
pubmed: 24098669
Health Serv Res. 2005 Dec;40(6 Pt 1):1918-30
pubmed: 16336556
Qual Life Res. 2017 Oct;26(10):2573-2592
pubmed: 28623442
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
Oncologist. 2012;17(11):1475-81
pubmed: 22933591
Health Serv Manage Res. 2017 Nov;30(4):197-212
pubmed: 29034727
Integr Cancer Ther. 2018 Jun;17(2):380-387
pubmed: 27585628
Implement Sci. 2016 May 17;11:72
pubmed: 27189233
Support Care Cancer. 2018 Apr;26(4):1221-1231
pubmed: 29098402
BMC Health Serv Res. 2015 Jul 01;15:252
pubmed: 26126998
BMC Womens Health. 2007 Mar 30;7:4
pubmed: 17397542
BMC Health Serv Res. 2016 Oct 12;16(1):570
pubmed: 27729079
JAMA Oncol. 2019 May 1;5(5):735-737
pubmed: 30973579
Health Serv Res. 2012 Jun;47(3 Pt 1):1201-23
pubmed: 22098418
BMC Public Health. 2013 Oct 30;13:1027
pubmed: 24172020
BMC Cancer. 2016 Nov 4;16(1):843
pubmed: 27809814
Int J Nurs Stud. 2014 Mar;51(3):495-510
pubmed: 24074939
Psychooncology. 2017 Jul;26(7):873-913
pubmed: 28691760
Cancer. 2016 Feb 15;122(4):598-610
pubmed: 26599199
J Oncol Pharm Pract. 2019 Jun;25(4):896-902
pubmed: 30808278
Support Care Cancer. 2017 Oct;25(10):3181-3190
pubmed: 28434097
Trials. 2015 Feb 15;16:51
pubmed: 25887713
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 27324111
PLoS One. 2016 May 13;11(5):e0154678
pubmed: 27177041
J Gen Intern Med. 2005 Aug;20(8):686-91
pubmed: 16050875